Search

Your search keyword '"Söling, Ulrike"' showing total 23 results
Start Over Author "Söling, Ulrike"
23 results on '"Söling, Ulrike"'

1. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Author

Kieback, Dirk Günter, van Mackelenbergh, Marion Tina, Hielscher, Carsten, Ugur, Mustafa Celalettin, Uleer, Christoph, Zahn, Mark-Oliver, Meyer, Ralf, Kraudelt, Susanne, Stefek, Andrea, Pink, Daniel, Just, Marianne, Kolberg, Hans-Christian, Fehm, Tanja, Malter, Wolfram, Warm, Mathias, Forstbauer, Helmut, Behringer, Dirk, Wortmann, Anke, Rom, Joachim, Lehnert, Antje, Ackermann, Sven, Guth, Dagmar, Simon, Eike, Dünnebacke, Jan, Hönig, Arnd, Ehscheidt, Peter, Gnauert, Karsten, Kühn, Thorsten, von Abel, Ekkehard, Hartkopf, Andreas, Karck, Ulrich, Negwer, Martina, Wacker, Jürgen, Welslau, Manfred, Sagasser, Jaqueline, Heinrichm, Bernhard, Brucker, Cosima, Stauder, Heribert, Gröll, Isolde, Felberbaum, Ricardo, Popovic, Milos, Baerens, Dirk-Toralf, Söling, Ulrike, Zaiss, Matthias, Rauh, Jaqueline, Fietz, Thomas, Schröder, Jan, Voß, Hermann, Mohm, Johannes, Neef, Ute, Rieger, Lorenz, Distelrath, Andrea, Nusch, Arnd, Schmidt, Burkhard, Lüdtke-Heckenkamp, Kerstin, Berghorn, Michael, Busch, Steffi, Schock, Caroline, Metz, Michael, Lorenz, Andreas, Uhlig, Jens, Otremba, Burkhard, Harbeck, N., Fasching, P.A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R.E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Schinköthe, T., and Schmidt, M.

Published
2023
Full Text
View/download PDF

4. Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Author

Decker, Thomas, Söling, Ulrike, Hahn, Antje, Maintz, Christoph, Kurbacher, Christian Martin, Vehling-Kaiser, Ursula, Sent, Dagmar, Klare, Peter, Hagen, Volker, Chiabudini, Marco, Falkenstein, Julia, Indorf, Martin, Runkel, Eva, and Potthoff, Karin

Published
2020
Full Text
View/download PDF

6. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials

Author

Dechow, Tobias, primary, Aldaoud, Ali, additional, Behlendorf, Timo, additional, Knauf, Wolfgang, additional, Eschenburg, Henning, additional, Groschek, Matthias, additional, Hansen, Richard, additional, Söling, Ulrike, additional, Grebhardt, Sina, additional, Siebenbach, Hans Ulrich, additional, Vannier, Corinne, additional, and Potthoff, Karin, additional

Published
2021
Full Text
View/download PDF

7. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Author

Eichhorst, Barbara F., Busch, Raymonde, Stilgenbauer, Stephan, Stauch, Martina, Bergmann, Manuela A., Ritgen, Matthias, Kranzhöfer, Nicole, Rohrberg, Robert, Söling, Ulrike, Burkhard, Oswald, Westermann, Anne, Goede, Valentin, Schweighofer, Carmen D., Fischer, Kirsten, Fink, Anna-Maria, Wendtner, Clemens M., Brittinger, Günter, Döhner, Hartmut, Emmerich, Bertold, and Hallek, Michael

Published
2009
Full Text
View/download PDF

8. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Author

Dechow, Tobias, Aldaoud, Ali, Behlendorf, Timo, Knauf, Wolfgang, Eschenburg, Henning, Groschek, Matthias, Hansen, Richard, Söling, Ulrike, Grebhardt, Sina, Siebenbach, Hans Ulrich, Vannier, Corinne, and Potthoff, Karin

Subjects
MULTIPLE myeloma, CLINICAL trials, DEXAMETHASONE, PROGRESSION-free survival, OVERALL survival
Abstract

Background: Prognosis of patients with multiple myeloma (MM) who have relapsed on or become refractory to immunomodulators and bortezomib is poor, and treatment options are limited. While pomalidomide plus low‐dose dexamethasone (POM/DEX) has demonstrated efficacy in clinical trials, real‐world evidence is scarce. Patients and Methods: POSEIDON was a prospective non‐interventional study designed to evaluate effectiveness, safety and quality of life (QoL) of POM/DEX in patients with relapsed or refractory MM (R/RMM) pretreated with at least two prior therapy lines including both lenalidomide and bortezomib in real world in Germany. Patients received POM/DEX according to physicians' choice. Data were analyzed descriptively. Results: Between 2014 and 2017, 151 patients were enrolled, 144 patients with a median of three prior therapy lines qualified for effectiveness analysis. Median age was 73.2 years. Median progression‐free and overall survival were 6.3 months [95% confidence interval (CI) 5.2, 8.6] and 12.9 months [95% CI 10.6, 15.1]. Most frequent grade 3/4 adverse events were leukopenia (8.2%), pneumonia (7.5%) and anemia (5.5%). QoL was maintained after start of POM/DEX. Conclusion: The results of POSEIDON support the effectiveness and safety of POM/DEX in R/RMM patients pretreated with lenalidomide and bortezomib and highlight the clinical value of the POM/DEX regimen in the real‐world setting. Registered at clinicaltrials.gov (NCT02075996). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

9. Abstract P5-11-14: Palbociclib in combination with anastrozole or exemestane as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study

Author

Welslau, Manfred, primary, Marschner, Norbert, additional, Söling, Ulrike, additional, Brucker, Cosima, additional, Stoetzer, Oliver J., additional, Meiler, Johannes, additional, Wimberger, Pauline, additional, Dörfel, Steffen, additional, Sahlmann, Jörg, additional, Houet, Leonora, additional, Vannier, Corinne, additional, and Potthoff, Karin, additional

Published
2020
Full Text
View/download PDF

10. TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Author

Ganster, Christina, primary, Schaab, Roxana, additional, Shirneshan, Katayoon, additional, Eder, Lea Naomi, additional, Mies, Anna, additional, Germing, Ulrich, additional, Elmaagacli, Ahmet, additional, Sole, Francesc, additional, Palomo, Laura, additional, Kaivers, Jennifer, additional, Söling, Ulrike, additional, Lange, Frank, additional, Kröger, Nicolaus, additional, Hertenstein, Bernd, additional, Döhner, Konstanze, additional, Bug, Gesine, additional, Hildebrandt, Barbara, additional, Talló Parra, Marc, additional, Nickelsen, Maike, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Bacher, Ulrike, additional, Braulke, Friederike, additional, Schanz, Julie, additional, and Haase, Detlef, additional

Published
2019
Full Text
View/download PDF

11. Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

Author

Eder, Lea Naomi, primary, Ganster, Christina, additional, Shirneshan, Katayoon, additional, Germing, Ulrich, additional, Elmaagacli, Ahmet H., additional, Mies, Anna, additional, Hertenstein, Bernd, additional, Simon-Becker, Susanne, additional, Platzbecker, Uwe, additional, Dierks, Sascha, additional, Rittscher, Katharina, additional, Schaab, Roxana, additional, Martin, Roman, additional, Söling, Ulrike, additional, Heudobler, Daniel, additional, Lange, Frank, additional, Hildebrandt, Barbara, additional, Glass, Bertram, additional, Braulke, Friederike, additional, Schanz, Julie, additional, and Haase, Detlef, additional

Published
2019
Full Text
View/download PDF

12. Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes

Author

Ganster, Christina, primary, Müller‐Thomas, Catharina, additional, Haferlach, Claudia, additional, Strupp, Corinna, additional, Ogata, Kiyoyuki, additional, Germing, Ulrich, additional, Hildebrandt, Barbara, additional, Mallo, Mar, additional, Lübbert, Michael, additional, Müller, Christel, additional, Solé, Francesc, additional, Götze, Katharina S., additional, Vandenberghe, Peter, additional, Göhring, Gudrun, additional, Steinmetz, Tilman, additional, Kröger, Nicolaus, additional, Platzbecker, Uwe, additional, Söling, Ulrike, additional, Raynaud, Sophie, additional, Shirneshan, Katayoon, additional, Schanz, Julie, additional, and Haase, Detlef, additional

Published
2019
Full Text
View/download PDF

17. Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Author

Stilgenbauer, Stephan, primary, Zenz, Thorsten, additional, Winkler, Dirk, additional, Bühler, Andreas, additional, Schlenk, Richard F., additional, Groner, Silja, additional, Busch, Raymonde, additional, Hensel, Manfred, additional, Dührsen, Ulrich, additional, Finke, Jürgen, additional, Dreger, Peter, additional, Jäger, Ulrich, additional, Lengfelder, Eva, additional, Hohloch, Karin, additional, Söling, Ulrike, additional, Schlag, Rudolf, additional, Kneba, Michael, additional, Hallek, Michael, additional, and Döhner, Hartmut, additional

Published
2009
Full Text
View/download PDF

18. Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Author

Stilgenbauer, Stephan, primary, Zenz, Thorsten, primary, Winkler, Dirk, primary, Bühler, Andreas, primary, Groner, Silja, primary, Busch, Raymonde, primary, Hensel, Manfred, primary, Dührsen, Ulrich, primary, Finke, Juergen, primary, Dreger, Peter, primary, Jäger, Ulrich, primary, Lengfelder, Eva, primary, Truemper, Lorenz H., primary, Söling, Ulrike, primary, Schlag, Rudolf, primary, Hallek, Michael, primary, and Döhner, Hartmut, primary

Published
2008
Full Text
View/download PDF

19. Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Author

Stilgenbauer, Stephan, primary, Winkler, Dirk, additional, Bühler, Andreas, additional, Zenz, Thorsten, additional, Groner, Silja, additional, Busch, Raymonde, additional, Hensel, Manfred, additional, Dührsen, Ulrich, additional, Finke, Jürgen, additional, Dreger, Peter, additional, Jäger, Ulrich, additional, Lengfelder, Eva, additional, Trümper, Lorenz, additional, Söling, Ulrike, additional, Schlag, Rudolf, additional, Hallek, Michael, additional, and Döhner, Hartmut, additional

Published
2007
Full Text
View/download PDF

21. TP53Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Author

Ganster, Christina, Schaab, Roxana, Shirneshan, Katayoon, Eder, Lea Naomi, Mies, Anna, Germing, Ulrich, Elmaagacli, Ahmet, Sole, Francesc, Palomo, Laura, Kaivers, Jennifer, Söling, Ulrike, Lange, Frank, Kröger, Nicolaus, Hertenstein, Bernd, Döhner, Konstanze, Bug, Gesine, Hildebrandt, Barbara, Talló Parra, Marc, Nickelsen, Maike, Glass, Bertram, Platzbecker, Uwe, Bacher, Ulrike, Braulke, Friederike, Schanz, Julie, and Haase, Detlef

Abstract

Introduction:Complex aberrant karyotypes (CK, ≥3 cytogenetic aberrations, CA) are associated with an unfavorable prognosis and an increased AML transformation rate in MDS. However, even MDS with CK (CK-MDS) are heterogeneous in terms of genetic profile and prognosis. Recently, we demonstrated that a high number of CA as well as mutations in TP53(TP53mut) are associated with increased risk in CK-MDS (Haase et al, 2019). However, as there is a strong association between CK-MDS and TP53mut, it is still a matter of debate whether the karyotype and TP53mutare prognostically independent genetic markers. Furthermore, loss of heterozygosity (LOH) of 17p13 (TP53LOH), due to loss of genetic material or to copy number neutral LOH (CN-LOH), is also associated with a poor prognosis. We here aimed to characterize TP53mutandTP53LOHin CK-MDS and to elucidate the impact of cytogenetics, TP53mutand TP53LOHon the outcome of CK-MDS.

Published
2019
Full Text
View/download PDF

22. Mutation Profile of PPM1Dand TP53in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

Author

Eder, Lea Naomi, Ganster, Christina, Shirneshan, Katayoon, Germing, Ulrich, Elmaagacli, Ahmet H., Mies, Anna, Hertenstein, Bernd, Simon-Becker, Susanne, Platzbecker, Uwe, Dierks, Sascha, Rittscher, Katharina, Schaab, Roxana, Martin, Roman, Söling, Ulrike, Heudobler, Daniel, Lange, Frank, Hildebrandt, Barbara, Glass, Bertram, Braulke, Friederike, Schanz, Julie, and Haase, Detlef

Abstract

Introduction: Complex (≥3) abnormalities (cA) are associated with an inferior outcome in myelodysplastic syndromes (MDS). About 50% of MDS with cA show mutations in TP53that might contribute to the formation of the cA and worsen prognosis (Haase et al., Leukemia, 2019). In former single nucleotid polymorphism (SNP) analysis we found chromosome 17q being affected in several patients with cA with a higher incidence as by chance. In just this region is a gene called PPM1Dlocated which already has been observed as one of the most frequently mutated genes in pts./individuals with clonal hematopoiesis with indetermined significance (CHIP). PPM1Dis encoding for a protein named Wip1. This protein acts as an inhibitor of p53. About 5% of MDS with 5q deletions show mutations in PPM1D(Panagiota et al., ASH 2017). Mutations in PPM1Dare even more common among pts with therapy-related MDS (15%, Lindsley et al., 2017). The aim of our study was to determine the frequency of PPM1Dmutations in MDS with cA and to shed light upon their possible contribution to the formation of cA.

Published
2019
Full Text
View/download PDF

23. TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (=3 anomalies) Aberrant Karyotypes

Author

Ganster, Christina, Schaab, Roxana, Shirneshan, Katayoon, Eder, Lea Naomi, Mies, Anna, Germing, Ulrich, Elmaagacli, Ahmet, Sole, Francesc, Palomo, Laura, Kaivers, Jennifer, Söling, Ulrike, Lange, Frank, Kröger, Nicolaus, Hertenstein, Bernd, Döhner, Konstanze, Bug, Gesine, Hildebrandt, Barbara, Talló Parra, Marc, Nickelsen, Maike, Glass, Bertram, Platzbecker, Uwe, Bacher, Ulrike, Braulke, Friederike, Schanz, Julie, and Haase, Detlef

Abstract

Germing: Jazz Pharmaceuticals: Honoraria; Novartis: Honoraria, Research Funding; Amgen: Honoraria; Celgene: Honoraria, Research Funding. Kaivers:Jazz Pharmaceuticals: Other: Travel Support. Kröger:Celgene: Honoraria, Research Funding; DKMS: Research Funding; JAZZ: Honoraria; Medac: Honoraria; Neovii: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Riemser: Research Funding; Sanofi-Aventis: Research Funding. Hertenstein:RS Media: Research Funding. Döhner:Daiichi: Honoraria; Jazz: Honoraria; Novartis: Honoraria; Celgene: Honoraria; Janssen: Honoraria; CTI Biopharma: Consultancy, Honoraria. Bug:Hexal: Membership on an entity's Board of Directors or advisory committees; Celgene Neovii: Other: travel grant; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead Sciences: Membership on an entity's Board of Directors or advisory committees, Other: Travel grants; Sanofi: Other: travel grants; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants; Jazz Pharmaceuticals: Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees. Nickelsen:Roche Pharma AG: Membership on an entity's Board of Directors or advisory committees, Other: Travel Grants; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant; Janssen: Membership on an entity's Board of Directors or advisory committees. Platzbecker:Celgene: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Novartis: Consultancy, Honoraria.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results